Jing Huang received her B.A. in Statistics and Probability from Peking University in 1997 and her Ph.D.in Statistics and M.S. in Epidemiology from Stanford University in 2002. She has been working in the biomedical field for over 15 years and her research interest focuses on statistical methodologies in clinical trial design, genomic analysis, and machine learning.
Her first job is at Affymetrix Inc. During her tenure there, she invented the first copy number detection algorithm using SNP chips to efficiently and accurately detect genomic aberrations without the need of a matched normal control. She is also among the first to discover and systematically catalog copy number variations (CNVs) in phenotypically normal populations. After that she worked as the principal statistician leading the analysis team in a small diagnostic company Aviir Inc; and then at Amgen Inc, pioneering exploratory biomarker strategies in all phases of clinical trials. She is currently the VP of Bioinformatics at Veracyte Inc., a molecular diagnostic company, responsible for designing, implementing and executing bioinformatics pipelines and statistical analyses across all phases of product development. Jing has authored more than 20 articles in peer-reviewed scientific journals and is a co-inventor of several patents. Besides her daily work, she actively promotes data science through many of her volunteer activities: She has been serving as reviewer for several statistical and bioinformatics journals and she is currently the president (term 2015-2016) of American Statistical Association San Francisco Bay Area Chapter (SFASA). She is also the general co-chair and local organization chair of the Fourteenth Asia Pacific Bioinformatics Conference (APBC 2016).
Ruixiao Lu, Ph.D.
Ruixiao Lu received her B.S. in Statistics from Peking University in 2003 and her Ph.D. in Statistics, with Emphasis in Biostatistics, and Designated Emphasis in Bioinformatics from University of California, Davis in 2007. She has been working in the biotech/pharmaceutical field for over 10 years and her research interest focuses on clinical trial design and monitoring, high throughput genomic data, and biomarker clinical utility in personalized healthcare.
Ruixiao started her first job at Affymetrix Inc., a pioneer biotech firm in quantifying genomic information using microarray, and she was the lead of developing an automated analysis workflow for SNP genotyping system Axiom. She then worked at Novartis for 5 years and expanded her career into clinical trials with biomarker applications, and was the biostatistics lead for several critical clinical trials and regulatory submissions within US and China. Ruixiao is now a Principal Biostatistician at Genomic Health, Inc, a leader in personalized healthcare, and focus on developing innovative methods and clinical study strategy in biomarker clinical utility. Given her unique experiences in all phases of clinical trials with extensive biomarker knowledge, she has also been providing consulting to product lifecycle management, working closely with R&D and Commercial leaders within the company.
Ruixiao has been actively promoting data science education through many of her volunteer work. She has been serving as reviewer for several peer-reviewed journals, and she has served as VP of Biostatistics (2012-2014) and then President (2014-2015) of American Statistical Association San Francisco Bay Area Chapter (SFASA). She is also among the local organization committee of the 14th Asia Pacific Bioinformatics Conference (APBC 2016).
Peng Yang, M.S.
Peng Yang is the founder and president of Clindata Insight Inc, based in Moraga, CA. Clindata offers consulting service in CDISC standards, NDA submission, statistical programming, biostatistics and data management area. Clindata also connects top-notch talents in biometrics with the right opportunities through full time placement and contracting arrangement. Before running her own business, she was working for pharmaceutical companies in various management roles including the head of statistical programming and data management. Ms. Yang has MS in Computer Science from University of Texas at Dallas and MS in Genetics and Developmental Biology from University of Texas Southwestern Medical Center in Dallas. For more information, please visit
Bin Chen, Ph.D.
Bin Chen, PhD, is a junior faculty member in the Institute of Computational Health Sciences at the University of California, San Francisco. Prior to this position, he was a postdoctoral scholar in Dr. Atul Butte’s lab at Stanford University. Dr. Chen trained as a chemist in college, worked as a software engineer before graduate school, trained as a chem/bioinformatician in graduate school, worked as a computational scientist in Novartis, Pfizer and Merck. He received his PhD in informatics at Indiana University, Bloomington. His primary research interest is to develop methods and tools on precision medicine and combinatory therapy in oncology. He has published over 25 papers and 1 book titled “Semantic Breakthrough in Drug Discovery”. He also actively consults for biotechs and organizes events in translational bioinformatics.
Xin Zhao, M.D., Ph.D.
Xin Zhao is a statistical leader with clinical background and broad experience in all phasesof clinical development and medical research in pharmaceutical and biotech industry. Xin grew up in China, received MD from Beijing Medical University (now named Peking University Health Science Center), and practiced as Obstetrician at Beijing Obstetrics and Gynecology Hospital. She received PhD in Statistics at Cornell University after discovering her passion in quantitative science. During PhD program, Xin was elected as the statistical consultant for a genetic lab at Cornell University to design and analyze microarray experiments, which resulted in multiple NIH grants and numerous biology and statistical publications in peer-reviewed journals. Over the last 10 years, Xin has accumulated experience in pharmaceutical and biotech industry including Merck and Johnson & Johnson, where she lead efforts to support neurology and oncology clinical development and provide statistical expertise in strategic planning of clinical programs, designing and analyzing clinical trials, and interactions with global health authorities for drug/biologics approval.
Xin’s primary research interests are in design and conduct clinical trials, Bayesian methods and adaptive designs. She was a cofounder for the Bayesian OpenBUGs Standardization Initiative, a joint effort among academia and pharmaceutical industry in USA and EU (2007-2012), served on the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partner Scientific Board (2012-2014), and currently is a member of DIA (Drug Information Association) Bayesian Statistical Scientific Working Group (2012-present).
Xin enjoys giving back to the biostatistics society and keeping herself current in statistical methodology and applications in drug development and medical research. She published over 15 papers in peer-review journals, gave invited presentations at various international statistical meetings, and currently serves as President Elect of the American Statistical Association San Francisco Chapter.
Haiyan Huang, Ph.D.
Haiyan Huang is currently an Associate Professor in the Department of Statistics at UC Berkeley. Meanwhile, she is affiliated with the graduate group in Biostatistics and the center for Computational Biology on campus. Prior to joining the faculty member of UC Berkeley, Haiyan Huang did a postdoc in Applied Statistics and Computational Biology at Harvard University. She obtained her Ph.D. in Applied Mathematics from the University of Southern California in 2001, and received a B.S. in Mathematics from Peking University, China in 1997.
As an applied statistician, her research is at the interface between statistics and data-rich scientific disciplines such as biology. Over the past few decades, rapidly evolving biological technologies have generated enormous high-dimensional, complex, noisy data, presenting increasingly pressing challenges to statistical and computational science. Her group has devoted to addressing various modeling and analysis challenges from these data.
Hua Tang, Ph.D.
Hua received her PhD in Statistics, with a minor in Genetics, from Stanford University in 2002. From 2002 to 2006, she was on faculty in the PHS division at the Fred Hutchinson Cancer Research Center. Hua joined the Stanford Genetics Department in 2007. The goals of her research are to better understand the evolutionary forces that have shaped the pattern of genetic variation in humans, as well as to elucidate the genetic architecture of complex traits and diseases in the context of human evolution.
For more information please visit
Rui (Sammi) Tang, Ph.D.
Dr. Rui (Sammi) Tang is a leading expert of biostatistics/bioinformatics in the biotech/pharmaceutical industry and she is currently a Biostatistics Director and the therapeutical area head of Oncology at Shire pharmaceutical. Prior to that she was at Vertex pharmaceutical leading Oncology and Hematology pipelines. Prior join Vertex she has worked at Amgen for about 8 years, Mayo clinical biostatistics and Merck shortly. Previously she served as the biostatistics lead of Companion Diagnostics and the Global Statistics Lead for multiple oncology clinical programs from early phase to late phase at Amgen. Sammi has great experience in CDRH, CBER, CDER, health Canada, EMA and Asian regulatory agencies interactions. Sammi’s research interests are primarily in the area of adaptive clinical trial design and biomarker subgroup related statistical issues in precision medicine. She has authored more than 20 articles in peer-reviewed scientific journals on methodology, study design, and data analysis and reporting and is a co-inventor of several patents. Besides her daily work, she actively promotes data science through many of her volunteer activities: She serves the organizing committee for the Fourteenth Asia Pacific Bioinformatics Conference (APBC 2016). She serves in the SCT (Society of Clinical Trials) scientific program committee since 2013 to help organize the annual international conference. She is leading teams in the DIA(Drug Information Association) small population working group for rare disease statistical methodology development. She is also an active member in ASA and ICSA to serve the biostatistics and data science professional community.
Sammi graduated from the University of Michigan Technology University with a PhD in statistics Genetics.
Ying Lu, Ph.D.
Ying Lu, Ph.D., is a professor of biostatistics in Stanford University School of Medicine. He also serves as the director of US Department of Veterans Affairs (VA) Palo Alto Cooperative Studies Program Coordinating Center (CSPCC), VA Palo Alto Health Care System. In the VA CSPCC, he directs a multi-disciplinary team to support the development, conduct, analysis, and publication of multicenter clinical trials initiated by VA investigators. Prior to his position at Stanford, he was a professor of radiology and biostatistics at the University of California, San Francisco (UCSF) and served as the director of the biostatistics core for the UCSF Helen Diller and Family Comprehensive Cancer Center, where he led the effort to support university wide oncology research and provided statistical expertise and research in developing and validating new diagnostic techniques and treatments.
Lu’s primary research interests are in design and conduct clinical trials, statistical evaluation of medical diagnostic tests and medical decision making. He developed new statistical design for phase I and II cancer trials, and recently works on phase I dose selection for combination of treatments. He is a member of American Joint Committee on Cancer (AJCC) Statistical Task Forces and members of several External Advisory Boards or Scientific Advisory Boards, including a member of the US Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory Committee (2007-2010).
Ying Lu grew up in China, received his BS in mathematics from Fudan University, MS in applied mathematics from Shanghai Jiao Tong University, and Ph.D. in biostatistics from the University of California, Berkeley. Dr. Lu is an elected fellow of the American Statistical Association, past president for the ASA Bay Area Chapter, a receipt of the Evelyn Fix Memorial Medal and the Healthstar Osteoporosis Medical Research Award (HOMA) for Achievements in Osteoporosis Research, and the 2014 President of the International Chinese Statistical Association.
Further information of Ying Lu can be found from the following link:
Lu Tian, Ph.D.
Lu Tian is an Associate Professor of the Department of Biomedical Data Science at Stanford University. He received his Sc.D. in Biostatistics from Harvard University. Dr. Tian has rich experience in conducting statistical methodological research, planning large epidemiological studies, running data management for randomized clinical trials and conducting applied data analysis. His current research interest is in developing statistical methods in personalized medicine, causal inference, survival analysis and high throughput data analysis.
Mike (Zhanzhi) Hu, Ph.D.
Dr. Zhanzhi Hu is a product developer with a successful track record of developing and launching genomics based products, with particular focus on molecular diagnostics. He started his career as a development scientist at Affymetrix where he focused on developing microarray based genotyping and copy number assay platforms. He then spent a few years at Complete Genomics, a leading next-generation sequencing platform company, to lead the effort in developing a robust and scalable NGS library preparation and sequencing assay with accompanying reagents. Currently serving as the Associate Director of Product Development at Veracyte, a molecular diagnostic company pioneering the field of molecular cytology to improve patient outcomes and lower healthcare costs, Dr. Hu leads the Product Development team working closely with the Marketing, Clinical, Quality and Regulatory teams to design, develop and launch advanced molecular diagnostic products to solve complex clinical problems by utilizing the latest genomics based technologies while following rigorous regulatory guidelines and the Design Control process.
Dr. Hu obtained his B.S. degree in Cell Biology and Genetics from Peking University, and his Ph.D. degree in Molecular Genetics and Microbiology from the University of Texas at Austin.
Hua Kay Yue is a certified public accountant in state of California. She has more than ten years of experience in public accounting and taxation. She is currently a partner with Marks & Devine CPAs. Kay graduated from Shanghai JiaoTong University with a B.S. degree in Applied Chemistry.